Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

324.07 +4.36 (+1.36%)
Streaming Delayed Price Updated: 12:08 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 84,226
Open 322.99
Bid (Size) 323.68 (2)
Ask (Size) 324.25 (3)
Prev. Close 319.71
Today's Range 322.60 - 325.98
52wk Range 266.98 - 417.81
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Forecasting The Future: 7 Analyst Projections For United Therapeutics
Via Benzinga
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-10.0%
-10.0%
1 Month
+9.8%
+9.8%
3 Month
+5.3%
+5.3%
6 Month
-13.4%
-13.4%
1 Year
+17.1%
+17.1%

More News

Read More
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property Product Safety
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors
Via Chartmill
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Earnings Scheduled For April 30, 2025
Via Benzinga
1 Safe-and-Steady Stock on Our Buy List and 2 to Ignore
Via StockStory
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central
Via StockStory
Examining the Quality Attributes of UNITED THERAPEUTICS CORP (NASDAQ:UTHR).
Via Chartmill
3 Big Reasons to Love United Therapeutics (UTHR)
Via StockStory
Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Following Peter Lynch’s approach: Does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) fit the bill?
Via Chartmill
The Top 3 Stock Picks at the World’s Greatest Hedge Fund
Via MarketBeat
Topics Regulatory Compliance
Exposures Legal Regulatory
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Potential Undervalued Opportunity
Via Chartmill
1 Value Stock Worth Investigating and 2 to Brush Off
Via StockStory
United Therapeutics (NASDAQ:UTHR) Reports Bullish Q1
Via StockStory
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Topics Government World Trade
Exposures Political Tariff
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Via Benzinga
This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Via Benzinga
Demystifying United Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025
From United Therapeutics Corporation
Via Business Wire
How does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) stack up against Peter Lynch’s investment principles?
Via Chartmill

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 324.07
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 06/06/25 12:08 PM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 14.55B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 15B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.